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Abstract
Quantitative systems pharmacology (QSP) modeling is applied to address essential questions in drug development, such as
the mechanism of action of a therapeutic agent and the progression of disease. Meanwhile, machine learning (ML)
approaches also contribute to answering these questions via the analysis of multi-layer ‘omics’ data such as gene
expression, proteomics, metabolomics, and high-throughput imaging. Furthermore, ML approaches can also be applied to
aspects of QSP modeling. Both approaches are powerful tools and there is considerable interest in integrating QSP
modeling and ML. So far, a few successful implementations have been carried out from which we have learned about how
each approach can overcome unique limitations of the other. The QSP ? ML working group of the International Society of
Pharmacometrics QSP Special Interest Group was convened in September, 2019 to identify and begin realizing new
opportunities in QSP and ML integration. The working group, which comprises 21 members representing 18 academic and
industry organizations, has identified four categories of current research activity which will be described herein together
with case studies of applications to drug development decision making. The working group also concluded that the
integration of QSP and ML is still in its early stages of moving from evaluating available technical tools to building case
studies. This paper reports on this fast-moving field and serves as a foundation for future codification of best practices.
Keywords QSP  Machine learning  Review  Commentary

Rationale
Predictive mathematical modeling has become an established element of drug discovery and development due to
the totality of its impact on individual programs predicting,
for example, preclinical-clinical translation, therapeutic
index, optimal dosing, and drug-drug interactions, as well
as reducing the size and number of clinical trials [1, 2].
Awareness of the need for modeling is being driven in
parallel with the establishment of high quality, high
dimensional preclinical and clinical data warehouses [3–5].
Approaches to predictive modeling have been developing

and recently receiving attention from two major directions:
quantitative systems pharmacology (QSP) which describes
hypothesized or assumed mechanistic relationships in a
mathematical formalism, and machine learning (ML),
which applies unbiased algorithms to explore correlations
in experimental data. The question is whether these two
apparently disparate approaches may be integrated, and
what value may arise from such integration (QSP ? ML).
This White Paper describes the current achievements
and possible future directions of early QSP ? ML work
from the perspective of the working group on QSP ? ML
within the ISoP QSP Special Interest Group (SIG). Membership of the working group reflects the diversity of
backgrounds and expertise in the QSP community, from
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academic research in mathematical biology and chemical
engineering to industry pharmacometrics applications.
Discussions of members’ research have covered a broad
range of methods and applications that are represented
here. Integrating QSP ? ML also spans a broad range of
research objectives from increasing physiological understanding and predictive power to reducing the computational burden and complexity of analyzing large QSP
models.
We begin with a brief review of the considerations of
QSP and ML separately. Considerations for integrated
QSP ? ML are organized into four categories of current
activity in the field, followed by illustrating case studies.
We conclude with operational concerns of implementing
ML within an existing pharmacometrics research groups
and end with a future perspective. A glossary of common
ML terms is provided as a quick reference. More specialized ML methods, not in common use, are included in the
overview of current methods with references as a guide for
interested readers.

Background
QSP modeling supports all stages of the drug
development pipeline
The term QSP was coined in 2011 in an NIH white paper as
an intersection of mathematical modeling and experimental
approaches focused on drug pharmacology [6]. QSP-based
predictive modeling using QSP has successfully supported
many facets of drug development, including regulatory
decisions [7–10], setting pre-specified goals for program
go/no-go decision points, characterizing physiological /
therapeutic mechanisms of action for single or combinatorial approaches, treatment optimization, and response to
proposed dosing regimens [11, 12]. Agharmiri et al. [13]
provides a comprehensive overview of QSP models, their
application, and growth across different disease areas over
the last three years (2018 to 2021).
The QSP modeling approaches apply existing knowledge of dynamical and nonlinear molecular mechanisms as
a theoretical framework to test our understanding, contextualize new data and predict the outcome of intervention. Several mathematical and computational approaches
have been used to encode QSP models, including ordinary
and partial differential equations (ODE, PDE), logic-based
methods, and constraint-based approaches [14]. It is the
representation of existing knowledge – the crafting of
assumptions – that presents the key challenges of QSP
modeling: the selection of key molecular drivers, the
generalization of mechanisms specific to physiological
context, disease and human sub-populations [15] and the
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assignment or derivation of (often unobserved) parameters
with the associated ‘‘curse of dimensionality’’ requiring
more data to cover the parameter space. Furthermore, QSP
modeling is labor-intensive. Model building is still largely
performed by manual distillation of a large volume of
scientific literature, often by one individual. Characterizing
the model (establishing accuracy, sensitivity, reducibility,
reproducibility) also requires manual distillation of available data and moreover, creates a substantial computational
burden since QSP models typically comprise dozens or
more dynamical variables and even more parameters.

Machine learning allows data driven analysis
as well as dimension reduction
Analyses of high dimensional data commonly leverage ML
approaches such as classification, regression, clustering,
associated rule learning, image processing, and ranking
(for a primer on ML for life scientists see [16]). The ability
to simultaneously observe 1000’s to 10,000’s of properties
of a system across multi-layer data (genes, proteins,
metabolites, etc.) does not require an assumption of key
drivers: all possible molecular players are analyzed. Furthermore, inference or discovery of unknown associations
among observables is possible. Inference has provided
functional annotation for unknown nucleic acid sequences
and characterized networks of associated functions among
observables. However, the identification of testable mechanistic hypotheses has been widely recognized as one of
the most significant challenges due to the general ‘‘blackbox’’ nature of ML approaches [17]. The strength of QSP
modeling to address this key weakness of ML, and the
strength of data-driven ML to address the QSP weakness of
manually building assumptions, suggests that integrated
QSP ? ML approaches offer the best of both.
It should be noted that the harmonization of data is one
of the most important considerations in the analysis of high
dimensional and/or integrated data. Preprocessing and
cleaning of data includes imputation of missing data, normalization, handling of categorical variables, and the
detection and handling of multicollinearity and systematic
bias/error. Data harmonization is a central consideration of
ML approaches but is also important in QSP models which
often rely on integrating data from multiple sources.
Another strength of ML is to help reduce the manual
labor, complexity, and execution of QSP modeling and
simulation. Because comprehensive QSP models can be
computationally expensive to solve and to characterize the
multi-dimensional parameter space, surrogate ML models
can be initially developed by training them with sample
input–output combinations from QSP models, and subsequently used for further predictions. Surrogate ML models
(or metamodels) have been used in engineering and physics
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to scale up simulations of multiscale models, providing
opportunities for the life sciences field to adapt some of the
methods [18].

Current approaches
The working group has identified four categories of
application for integrated QSP ? ML approaches.
(1)

(2)

(3)

(4)

Parameter estimation and extraction. Inferring
parameter values for defined QSP models and
reconciliation of model behavior with published
qualitative and quantitative data
Model Structure. Inferring relationships including
logic networks of large QSP models from a variety of
data types. Related to this are methods enabling the
evaluation of sensitivity and uncertainty of parameters and model structures including constraint-based
approaches. These methods also are applied to
extracting conclusions from heterogeneous populations of QSP models.
Dimension reduction. Methods to extract variables
from high dimensional data, whose behavior most
informs outcome.
Stochasticity and virtual populations. The assessment
of stochastic considerations such as predicting the
impact of genetic variants and mechanistic sources of
variability

Parameter estimation and extraction
Parameter estimation methods for large scale systems of
differential equations are, from a numerical analysis perspective, problems of minimization or maximization of a
defined cost function. In general, most ML problems
reduce to optimization problems. Parameter estimation
methods have been reviewed extensively (see for e.g. [19]).
For QSP models, the estimation is chronically under-determined due to limited clinical and preclinical pharmacology data [20]. Successful approaches have begun with a
characterization of parameter space [14] using, for example, virtual populations [21, 22] to find parameter sets that
generate outputs to be consistent with observed clinical
data. Additional virtual population considerations are
needed for strongly nonlinear models [23].
Successful implementation of ML for the direct analysis
of pharmacometrics data hinges on the robustness of
datasets for training and testing that capture the distribution
of intrinsic and extrinsic factors of interest. Clinical trial
data may not be suitable if the trial is small or has missing
or irregular data. Furthermore, there may be no clear
mechanistic association from clinical events to individual
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patient characteristics and/or QSP model parameters. ML
has been applied to identify such associations as described
in the thrombosis prediction case study, below [24]. In this
example, logistic regression was used to generate the
probability of a clinical event for each virtual patient
simulated from the QSP model. Other methods, such as
gradient boosted decision trees, deep neural networks and
multitask deep learning (MDL) may also be used. MDL or
transfer learning can simultaneously use features or
biomarkers as input data and predict multiple clinical
events or outputs. This allows the use of a large dataset to
improve the prediction accuracy of small data sets and has
been used, for example, to classify biological phenotypes
from images [25].
Semi-automated extraction of parameters from the literature has also been accomplished using natural language
processing, however additional analysis is required to
ensure the extracted data are applicable in a particular QSP
setting. Together with a ML model checking framework
[26], this approach has been applied to a combined of
parameter selection and QSP model selection to model
immune dysregulation in children prone to a specific viral
infection [27].

Model structure
ML methods to identify QSP model structure in a datadriven manner rather than a manual digest of prior
knowledge is an active area of method development.
Application to drug discovery and development is underway with some published exploratory case studies, however these methods have not yet been widely assessed or
validated.
The ML methods that have generated the most case
studies have focused on identifying the regulatory mechanism logic of gene expression, signaling pathways and cell
fate. These methods pragmatically focus on semi-quantitative data that are typically used to investigate biological
decision pathways and have developed alongside refinements in the generation of experimental data. As experimental perturbations can improve our understanding of
regulatory pathways [28], rich mutliplexed data are being
coupled with ML-based model structure generation to
identify therapeutic approaches, for example, to control
cell fate [29] and to identify personalized cancer therapy
[30]. These approaches offer the opportunity to build a
QSP model supporting the full pipeline of activities starting
with target identification, validation, and model refinement
as questions become more focused later in clinical
development.
Traditional ‘‘black box’’ deep learning approaches like
convolutional and recurrent deep neural networks eschew
prior information for neural network flexibility. In
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comparison, mechanistic models such as QSP models
routinely incorporate prior mechanistic understanding,
such as the prior models themselves as the structural prior
to reduce the data requirements (Fig. 1). The practice is
gaining new momentum when combining with the modern
computational power in the research field of scientific
machine learning (SciML) (also sometimes referred to as
physics-informed machine learning or science-guided
machine learning) and uses several different approaches to
incorporate known mechanism into machine learning
architectures and training processes.
One branch of SciML focuses on Physics-Informed
Neural Networks (PINNs) [31] which has been applied in
systems biology to generate Biologically Informed Neural
Networks [32]. In this approach, mechanistic regularization
is added to the neural network by modeling the neural
network NN(t) as the solution to the QSP model repre0
sented by an ODE u ¼ f ðu; tÞ. These techniques have been
shown to perform well on sparse data by using the model
form to compensate for the unknown quantities. In this
formulation, parameter estimation can be performed
simultaneously to the neural network training process,
making it potentially a tool for identification with small
data. In addition, one can choose neural architectures
which impose constraints that must be satisfied in the
evolution of the system. In fluid dynamics, this has been
shown to improve data efficiency even further [33]. However, this method is very computationally expensive. A
comparison of standard ODE solver based parameter estimation with the DeepXDE package [34] used in Biologically-Informed
Neural
Networks
showed
local
optimization of parameters was 100 9 to 10,000 9 more
expensive than traditional approaches [35].
Another SciML approach is ‘‘grey box’’ modeling using
the neural network as a universal approximator to represent
unknown portions of models. This is the approach taken in
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the universal differential equation framework [36], also
referred to as hybrid models or grey-box models with
universal approximators. Universal ODEs can be simplified
0
to the form u ¼ f ðu; NN ðuÞ; tÞ. For example, a one-compartment pharmacokinetics model with unknown nonlinear
feedback can be expressed in the form:
0

½Depot ¼ KaNN ð½½Depot; ½CentralÞ
0

½Central ¼ KaNN ð½½Depot; ½CentralÞ 

CL
½Central
V

where the final activation of the neural network could be
chosen to impose positivity of its output. Such a form can
then be used to extend full mechanistic models to find
terms missing from the original description via symbolic
regression. This approach has been demonstrated in other
fields such as battery engineering [37] and climate modeling [38] increasing the prediction accuracy over state-ofthe-art mechanistic models with only mild data requirements. This approach has also been extended to Bayesian
probabilistic forms [39] for calculating the probability of
missing or unknown mechanisms. Universal differential
equations do require specialized numerical differential
equation solver implementations like DiffEqFlux in order
to be accurately and efficiently trained.
Recent ML research has focused on addressing computational challenges specific to QSP modeling such as
stiffness. Techniques like PINNs can be susceptible to
training failures on highly stiff models [40] potentially due
to neural networks having a low frequency bias [41]. New
architectures [42, 43] have been developed for stiff biophysical models where approaches such as PINNs, recurrent neural networks, long short-term memory networks,
and convolutional neural networks can fail due to an illconditioned optimization process. More specialized architectures will likely be required to reach the accuracy and
robustness for ML applications in QSP.

Dimension reduction

Fig. 1 Scientific machine learning is model-based data-efficient
machine learning. How do we simultaneously use both sources of
knowledge? While lack of prior knowledge of mechanism can be
supplemented by machine learning on data, scientific machine
learning methods show that machine learning on small data can be
supplemented by encoding mechanistic principles into the machine
learning architectures. Thus, the important factor for achieving good
predictive power is the total combination of data and mechanistic
information encoded into these hybrid models
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Since the aim of a QSP model is putatively to understand
molecular interactions at the site of action and their impact
on the overall physiology of long-term disease progression
in general and different sub-populations, it is expected that
QSP models operate on multiple time and length scales i.e.
in a high dimensional space. In order to model these
complex systems, dimension reduction methods are often
used [44, 45]. These methods identify a subset of variables
and parameters that describe the mechanisms of interest,
optimally balancing computational performance and complexity [46, 47]. Dimension reduction is helps with interpretability of a model, since an overly complex model may
obscure a decision maker’s ability to establish
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interpretable hypotheses. Thus, trade-offs between performance and complexity need to be balanced [46, 48].
Indeed, feature selection (FS) can assist in the identification of a maximally informative subset of variables that
capture the essential behavior of a system. FS is a central
problem of ML, where a minimal subset of inputs (features) is selected according to a defined criterion (e.g. a
subset of genes whose expression predicts response to a
drug treatment. FS methods are data-driven and can inform
QSP model structure by identifying the minimal physiologically meaningful representation to enable mechanistic
interpretation and prediction [49]. The higher efficiency
achieved using FS is clear when comparing a FS ? QSP
strategy with a more traditional QSP model dimension
reduction strategy (Fig. 2).
(a)

(b)

FS ? QSP. Starting with all measured features, FS is
performed to identify the subset for QSP modeling.
The reduced model is parameterized and checked,
and feature selection is re-evaluated until an optimal
structure is identified.
QSP only. A QSP model is built using the complete
feature set, parameterized, checked, and dimension
reduction techniques are applied. As required,
dimension reduction, parameterization and/or checking are re-evaluated until an optimal model structure
is identified.

This simplified strategy of FS ? QSP considers an
independent FS method. However, it is difficult to decouple FS from other ML approaches that may also be applied
to a specific question or context. It is thus difficult to
propose universal and ubiquitous methods for FS and
dimension reduction. Comprehensive analyses [50] have
helped drive a consensus that univariate FS methods
treating variables independently and one-at-a-time are
suboptimal and should be applied in consideration of the

Fig. 2 Procedure for integrating ML and QSP modeling in two
different ways. Top: ML algorithms could be used to select features,
which then could be used to develop QSP models that include only
the highly relevant features; Bottom: alternatively, comprehensive

9

ML task. Thus, the three broad categories of FS algorithms
– the filter, wrapper and embedded approaches – include
this consideration [51, 52]. Filter methods resemble an
unsupervised approach, where FS is performed independently of ML. Wrapper methods resemble more supervised
methods in the sense that feature selection is validated
based on the performance of the subset to specific ML
tasks. Embedded methods perform the ML and FS tasks
simultaneously by incorporating (embedding) the FS
within the learning algorithm. Embedded methods usually
incorporate FS in the form of a set of constraints in an
overall multi-level optimization problem which attempts to
maximize the ML task while simultaneously minimizing
(some metric of) model complexity [53–55].
FS algorithms can be further classified as: (a) methods
that preserve the nature and meaning of the features
resulting in a ‘‘reduced’’ dimensionality representation
composed of a true subset of the original feature set; and
(b) transformation methods whereby ‘‘new’’ features are
created through manipulations; i.e. linear or non-linear
transformations of the original features [56]. Each class has
its own advantages and disadvantages, with the most
obvious being that purely reduction methods preserve the
nature, character, and physical meaning of the features and
as such model development and/or interpretation comes
more naturally. On the other hand, transformation methods
can achieve substantial dimensionality reduction – since
the variables are replaced with complex transformations of
the original features. However, the interpretation of the
transform variables becomes quite challenging: transformed variables become (non)linear functions, or projection on (non)linear spaces of the original variables and
have, therefore, lost their physical meaning. Interpretation
becomes important as we move towards the development
of, so-called, digital biomarkers able to predict [57].

QSP models that include most features could be first developed, then
ML algorithms and sensitivity analysis could be used to reduce the
scale of QSP model until smaller, more focused QSP models are
achieved
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The search for quantitative structure–activity relationships (QSAR) is one of the fields that have most benefited
from combined developments in ML and FS. QSAR brings
together a multitude of interesting problems: (1) a rich and
non-uniquely defined input space, since often molecular
features are computationally defined expressing a multitude of structural characteristics and molecular descriptors;
(2) a formidable ML problem since the relations between
structure and activity need to be inferred; and (3) by its
nature the feature space can easily become very high-dimensional, thus necessitating the reduction of its dimensions [50, 52, 58].

virtual population QSP models. Novel generative adversarial network (GAN) configurations have been shown to
allow for construction of populations deterministic models
[70] by addressing complex model parameter inference
scenarios involving data from heterogeneous populations.
Sensitivity analysis, uncertainty quantification and virtual population generation requires performing hundreds of
thousands of model simulations, another example of the
need for ML-facilitated dimension reduction.

Stochasticity and virtual populations

The utility of the integrated QSP ? ML approach is, of
course, to support decision making during drug discovery,
development and registration. Application of a QSP ? ML
approach requires a determination of the key decision to be
addressed, how the model will inform the decision, and
how quickly the decision is needed. This will, in turn,
determine the balance between pragmatism and deep
mechanistic understanding that is required. A number of
case studies are reviewed, illustrating current impact of the
QSP ? ML method.

There are additional case studies of ML applications in
pharmacometrics that do not yet create their own category
[59–61], including the use of stochastic approaches to
predict the effect of random genetic evolution or small
populations [62, 63]. However, stochastic approaches are
more widely used for the generation of virtual patient
populations.
Achieving increased confidence in QSP model predictions for critical decision-making requires model calibration, parameter estimation, sensitivity analysis, uncertainty
quantification, and generation of virtual patient populations. Related to their use in parameter estimation, virtual
patient populations are used to simulate how variability in
patient physiological characteristics explains mechanistic
contributions to the variability in response to drugs or other
clinical outcomes. The use of virtual population modeling
has gained significant attraction over the last decade
[21, 64–66]. Traditional methods employ initial sampling
of a subset of model parameters to construct a large set of
potential virtual patient candidates followed by a filtering/
rejection step based on different constraints to generate the
final population. The method ensures that the final population of models comprise physiologically plausible models
constrained by the feature ranges in the observation. ML
methods such as prevalence weighting and other heuristic
methods that use Markov chain Monte Carlo sampling
have been used to construct virtual population that match
the proposed data density [21, 22, 64, 67, 68].
The inverse problem of inferring parameters of the
mechanistic model has often been formulated as a Bayesian
inference problem. Novel generative ML models, such as
flow and generative adversarial network normalization, are
increasingly investigated for parameter inference of
mechanistic models and virtual population constructions
[69–71]. Normalizing flow-based methods are currently
used to infer stochastic model parameters in cases where
experimental data are acquired from a single individual
[71, 72], but they can be readily extended to construct
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Case studies

Prediction of therapeutic window for thrombosis
treatment
QSP modeling in thrombosis can shed light on important
aspects of hemostasis and thrombosis [73, 74]. Mechanistic
models of the coagulation pathway, and more generally
thrombosis, have been used extensively to characterize the
kinetics of coagulation and clot formation [75]. Linking the
mechanistic outputs of such a model to the clinical endpoints that are reflective of the benefit and risk balance of
anti-coagulant therapy should be possible. However, there
is uncertainty regarding the mechanistic relationship
between clot formation and venous thromboembolic events
and bleeding. Because of this uncertainty, machine learning was used to help quantify those relationships [73, 74].
The suitability of clinical data for ML can be limited.
QSP models can generate data to represent population
uncertainty, such as age, gender, pre-existing conditions,
missing dose, but still give the output in a uniform manner,
which is more suitable for ML. Associations between
simulated patient characteristics and multiple trial events
may provide insight due to the effects of undescribed
biological and physiological mechanisms. Real world event
rate data reported from multiple trials using different drugs
at different doses was used to tune an event prediction
algorithm.
The application of this QSP and ML approach supported
clinical development of anti-coagulants, including comparing them to competitor molecules and standards of care,
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informing the design of the venous thromboembolism
(VTE) prevention trials in orthopedic surgery, comparing
the efficacy and safety of the lead vs. backup, evaluating
potential combination therapies, and predicting dosing and
therapeutic window for VTE treatment and prevention.

Prediction of drug induced liver injury from QSP
and gene expression data
Although empirical PK/PD is commonly applied to model
toxicity, QSP modeling of injury at the cellular and tissue
levels – quantitative systems toxicology (QST) – offers
advantages for species translation and understanding
intraindividual differences that could improve toxicity
prediction [76]. The integration of QST with omics data is
the subject of the TransQST consortium [77]. An early case
study of the approach coupled a QSP model of liver
homeostasis with in vitro data to predict in vivo toxicity
[78]. A general theoretical framework to generate QSP
models from curated networks and expression data was
proposed by Kulkarni et al. by focusing on gene regulatory
networks alone [79]. Following this approach, interactions
between genes and known hepatoxicity mechanisms were
identified from the literature using natural language processing and used to expand a prebuilt QSP model [80]. The
QSP model described the mechanisms of necrosis, steatosis
and cholestasis comprising 112 coupled differential and
algebraic equations were constructed, including fat,
antioxidant and bile metabolism and transport. Toxicogenomic data was then generated for a specific drug of
interest, and ML used to find the differentially expressed
genes. The gene list was overlaid on the expanded ML ?
QSP network to convert gene-level changes into hypothetical perturbations of the ML ? QSP homeostasis.
Simulations were run to understand the relative impact of
multiple mechanistic perturbations, and to predict
hepatotoxicity.

QSP model structure inference and reduction
of high dimensional data
Reduction of high dimensional data: Boolean networks
and circadian pharmaco-pathomics
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Regulatory network prediction of T cell differentiation
The immune system has been modeled by a variety of
mathematical approaches, including ODE-based models
[82]. The data generated to investigate mechanisms of
immune cell activation are predominantly semi-quantitative, with the important aspects being the presence or
absence of signaling molecules such as cytokines and the
identity and activation state of immune cells measured, for
example, by the expression of cell surface markers such as
CD4, CD8, CD28 etc. The concentrations of cytokines over
time, frequency of cell counts, and other quantitative
measures over time may also be of interest but are more
difficult to determine.
Modeling the regulatory decision pathways of cell
activation using a logic-based approach is a natural way to
represent available data [83] and allows the prediction of T
cell fate. In particular, proper activation and differentiation
into specialized effector T cells and inducible regulatory T
cells are essential for orchestrating the balance between
protective immunity and undesired inflammation suppression. Plasticity, the ability to change phenotype and acquire
mixed or alternative fates, is a critical property of T cells,
enabling them to adapt their function and response to
changing environments and contexts. Extracellular cues
regulate T cell plasticity via complex signaling, metabolic,
and epigenetic networks. The ability to design T cell
microenvironments that can elicit specific programming
regimes has translational potential for many diseases (e.g.,
cancer, autoimmune diseases, and transplantation). To
understand better how extracellular cytokine milieu and
signaling drive T cell differentiation, a logical model of
signal transduction networks has been used to comprehensively interrogate its dynamics under hundreds of
environmental conditions. ML-based classification of the
dynamic response resulted in new evidence that T cell fates
depend on specific combinations of stimulating cytokines
and quantitative (dosage) and temporal (timing) dynamics
[84, 85] and discovery and characterization of novel
complex (multi-fate) T cell phenotypes [84, 86] as well the
extracellular ‘‘recipes’’ that can potentially regulate the
balance of each phenotype [84].
Reduction of high dimensional data: network inference

Boolean networks model the binary on/off behavior of the
variables (elements of the network) and infer the simplest
structural relationships that describe the overall behavior of
the system, most often applied to describing transcriptomic
network behavior. Recent work developed methods for the
identification of causal relationships within high dimensional data and for complex dynamic behavior such as
circadian rhythms [81].

Vaccine hyporesponse in the elderly is associated with
chronic inflammation and has been studied using multilayer molecular profiling in order to identify mechanisms
to target for therapeutic discovery [87]. In order to design a
new study to meta-genomic profiling of microbiome, a
non-human primate (NHP) study was performed to
understand how changes in host immune system response
to vaccination (or lack of response) was associated with
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changes in microbiome in old versus young animals [88].
The purpose of these studies was to characterize the
behavior of molecular entities that may play a role in
diminished vaccine response in older adults as targets for
vaccine adjuvant discovery. The ML-based analyses
reduced a very large set of data to a small, interpretable set
of interactions to support adjuvant identification, and to be
developed into a QSP model to support adjuvant validation
and the putative clinical development program.
A novel machine learning method was developed with
the above considerations [48]. The method identifies the
subset of entities (e.g. genes, proteins, metabolites, cell
types) that is the most useful for predicting the behavior of
the whole system. It provides important improvements on
similar methods, eliminating the need for the user to adjust
machine learning parameters that is typical for such
methods, and producing a sparse, parsimonious network.
Importantly, the method is independent of the distribution
of the data, allowing the integration of disparate data types
– transcriptomic, proteomic, metabolomic, cell profiling,
and demographic data from each subject. Both human and
NHP vaccine hyporesponse data [87, 88] were analyzed
and the network of entities in common between datasets
was identified. Functional annotation [89] and visualization
was performed manually in collaboration with bench scientists to interpret how sub-networks were connected.
From this process, the structure of interlinked pro-inflammatory pathways including IL-6, Il-23, monocyte and
dendritic cell activation, TNF-alpha and T-cell differentiation were identified to influence B cell class switching and
overall response. The relationships between microbial
metabolites and dendritic cell maturation as well as B cell
antibody production were proposed [90]. These hypotheses
are being tested using data from an on-going study.

Conclusions, discussion and future
perspective
Practical considerations: Implementing ML
in a drug discovery & development setting
The adoption of new technologies generally follows the
same lifecycle. At first, there will be a group of innovators
and early adopters, which eventually leads to a majority
group of users (both early and late stage), followed by a
group of late-comers [91]. At the same time, the technology itself has a lifecycle as it changes from a new technology to a growth technology to a mature technology to a
declining technology. ML is an interesting case because it
has been around for decades; it is really only recently, with
the advent of new hardware and algorithm advances, that
ML has seen increased adoption in science and society. ML

123

Journal of Pharmacokinetics and Pharmacodynamics (2022) 49:5–18

overall is probably in the mature stage of development, but
in the growth use phase within society. Within the pharmaceutical industry, the use of ML is not as advanced as
other industries, and may still be in the early adopter stage,
as companies are starting to identify applications for ML in
both the commercial and development space. Whether ML
succeeds and becomes the transformative technology in the
pharmaceutical industry remains to be seen.
Henstock [92] argues that implementing ML within a
company follows a hierarchical approach, which he refers
to as the ‘‘AI hierarchy of needs’’. Based on Maslow’s
hierarchy of needs for personal growth, lower levels of the
hierarchy must first be satisfied before moving upwards to
the next level (Fig. 3). At the very bottom of the hierarchy,
there must be data, algorithms, and hardware before one
can even think about using ML. Then the company needs
to be aware that ML can be used to solve the problem.
Once aware, companies realize they do not have the
expertise themselves to solve it, so they must contract or
partner with others that can. Over time, the company starts
to build the resources to do ML internally and eventually
starts to do so. With continued effort these capabilities
mature, and the company becomes reliant on ML, capable
of handling most problems with their own internal solutions, before maturing into a full-fledge AI-driven organization, where the company derives its competitive
advantage from its ML algorithms. Most Pharma companies are somewhere between the AI Outsourcing and
Collaboration stage and ML-capable stage. No pharma
company is AI-driven, and one could even argue that this
may be impossible for a Pharma company; that Pharma
should target an AI-enabled organization where AI is just
one factor used to derive its competitive advantage.
To start to implement ML within a company requires the
obvious resources like qualified personnel and computer
hardware/software able to process big data. Further, there
are cultural constructs that can improve the adoption of ML
at a company [93]. Below are a few constructs identified
from experience to improve the success of ML at a
company.
ML can be oversold as a magic solution to every
problem, but it is not. The lay press has given the
impression that ML will one day rule the world (as in
science fiction movies). However, ML does have its limits
despite the great strides in the use of ML from self-driving
cars to improving health care that have demonstrated the
vast potential of the approach. The right framework to
think through is how to better understand an organization’s
decisions, how those decisions are currently made, when
are they going to be made in the future, what information
would be helpful to have at the time of the decision being
made, and then, finally, how the data can be collected,
processed, analyzed, and translated into an insight to

Journal of Pharmacokinetics and Pharmacodynamics (2022) 49:5–18

13

Fig. 3 QSP ? ML Hierarchy of
Needs. Based on Maslow’s
Hierarchy of Needs, companies
must satisfy lower levels before
moving to higher levels.
Additionally, QSP models
establish the framework for
identifying the most informative
data for scientific discovery,
requiring an iterative workflow
to generate new data

inform that decision (Ryan Moore, personal communication, 2021). Sell the vision of what ML looks like when
effectively integrated into this framework.
When first starting a ML group, don’t let the first
problem you tackle be a ‘‘moon shot’’. Don’t start with a
big problem. Start small. Look for quick wins and early
successes. First impressions matter. Tackling a hard problem and producing a less than satisfactory result will tarnish the perception of all future work, particularly when
other projects fall short. Start with a smaller problem and
compare results to traditional methods. For example, a
supervised classification problem could compare a neural
network to results from a logistic regression analysis. Once
the group has some successes under their belt, start to
tackle bigger, more ambitious projects, and then move onto
the ‘‘moon shots’’.
Collaboration is mission-critical. Often the data scientists performing the ML do not have the same skill set as
the subject matter experts of the problem at hand, an
example being using ML to classify the presence or
absence of tumors in radiological scans (few radiologists
can program use ML). Whatever projects are started, they
should be done in a collaborative, inter-disciplinary manner. Data scientists should never work in a silo and then
present their results to teams after the analysis is complete.
Working in a collaboration leads to ‘‘buy-in’’ from all team
members and a sense of ownership in the results, which
may lead to greater use adoption in the future. Collaboratory teams can also lead to synergies, or identify project
bounds, that a single data scientist may not be aware of. At
the same time, the data scientist should be aware of turf
issues among groups. For example, there has always been
an uneasiness between ML and statistics (and the age-old

question – ‘‘what is the difference between ML and
statistics anyway?), which may translate to how these
groups work together. Going back to the use of logistic
regression for classification, traditional statistics groups
may see that as their purview and may not be happy with
another group doing it, so it’s important to be aware and
delicate in this regard.
Communication is the key to success and there are many
facets to this. First, there must be clear communication and
agreement on the problem to solve. Albert Einstein once
said that ‘‘If I were given one hour to save the planet, I
would spend 59 min defining the problem and one minute
resolving it.’’ A great solution is worthless if it solves the
wrong problem. Second, the importance of hiring data
scientists that can explain what it is they are doing cannot
be overstated. Invariably, ML presentations to non-ML
scientists require at least some level of explanation
regarding the methods being used. Data scientists that
cannot explain their methods in everyday language lower
the chance for a particular model to be accepted and
adopted. Some companies have taken to hire model
translators, who are not involved in the actual modeling
itself, whose job is to translate the problem to the data
scientists and then to help the data scientists explain the
mechanics and modeling results into common language
that everyone can understand it.

Challenges and future perspectives
The current state of the art does not include fully integrated
hybrid QSP ? ML models. The case studies presented are
ML-assisted QSP modeling, using ML to address weaknesses of QSP models. ML can be applied to parameterize

123

14

QSP models, analyze QSP model simulation, optimize
computational burden and one-time feature selection to
inform QSP model structure. The desired future state is to
use hybrid models to iteratively uncover black box mechanisms through rigorous, systematic analysis, linking
therapeutic interventions to the probability of clinical
events.
From our perspective, the success of developing new
drug therapies will be increased if QSP modeling is applied
earlier and deeper. For example, even before data is collected, QSP models serve as a framework for a research
team to align on assumptions, to prioritize the key gaps
where data should be collected, and to design experiments
that maximize the value of the investment into new data
generation. Integrating ML into this process enhances all
aspects of this process.
A continuing challenge is the lack of high-quality, highvolume clinical data. Advances in the technologies supporting decentralized trials such as smart phones, wearable
and blood self-collection devices, and in the establishment
of collaborative clinical data warehouses, offer new data
resources but are accompanied by new challenges in
bridging and integrating data. ML is used to simulate QSP
models, generating virtual patients that reflect variability of
model parameters. This approach is used to predict distribution of response given, for example, genotypic characteristics of a population. Hybrid QSP ? ML models
improve this surrogate model approach by concurrently
optimizing model structure with simulation, rather than
building the simulations from a fixed QSP model.
The next generation of QSP modeler will be called upon
to cross yet more interdisciplinary boundaries. The successful impact of QSP is entirely due to the mathematical
modelers who are also disease biologists and clinical
pharmacologists, delivering analyses. These modelers
successfully addressed key questions during the development process, through regulatory agency submissions, that
could not otherwise be answered. The expertise of
numerical analysts is now needed to build the collaborative
expertise necessary for identifying and addressing a new
class of questions. ML expertise conversely promises tools
for automating the modeling process and providing
accessibility for non-modelers and modelers, alike (does
one have to be an auto mechanic to drive a car?).
The integration of QSP and ML is in its early stages of
moving from evaluating available technical tools to
building case studies. Such integration offers multiple
advantages from providing data-driven QSP model
parameterization, to imposing a QSP model framework to
increase interpretability of high dimensional data and fully
data-driven QSP model structure discovery.
Driven by advances in data acquisition and warehousing
technology, as well as the improved understanding of key
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questions where QSP ? ML can add significant value, the
field is rapidly moving and we envision that the guidance
for best practices will soon be needed. We hope the current
perspective and review provides a snapshot of the rapidly
developing field and evolves into such guidance with the
continuous contribution of the QSP ? ML community.

Glossary
Black box

Constraint-based
approaches
Deep neural
networks

Digital biomarkers

Feature selection
Generative adversarial network

Grey box
Machine learning
(ML)

Neural network
(NN)

Pharmacopathomics
Predictive
Modeling
QSP modelling
Rich mutliplexed
data
Scientific machine
learning
Surrogate machine
learning models

A model for which the inputs and outputs are
observable but not the internal workings e.g. it
is not possible to determine which features of
an image are used by facial recognition
algorithms
Approaches to generate a solution to a mathematical model that impose conditions such as
minimum and maximum values
Neural network inputs and outputs are connected via one or more hidden layers. Deep
neural networks are those with many hidden
layers that allow the neural network to learn
more complex patterns in training data
Physiological and behavioral data collected and
measured by means of digital devices such as a
Holter monitor
The process of selecting a subset of data to aid
in interpretation
A field of ML that uses an unsupervised
‘‘game’’ to improve a neural network model.
The generator generates neural networks and an
adversarial network compares outputs: both
improve over repeated cycles
A model that combines known and estimated
(unknown) terms and/or equations
The study of computer algorithms that learn
and adapt without following explicit instructions, to analyze and draw inferences from
patterns in data
A mathematical function built from layers of
nonlinear transformations. The approach is
inspired by the way neurons are hypothesized
to interact during learning: a network connection strengthens if is excitatory and weakens if
inhibitory.
Automated machine learning-based classification of pathology images generated in clinical
pharmacology trials
Modeling that predicts the response of a change
to the system
Modeling to describe quantitative interactions
between a drug and the human system
Multiple datasets generated from a single set of
samples. Implies profiling data such as transcriptomics, proteomics, and metabolomics
A form of machine learning which incorporates
mechanistic scientific laws into the learning
process or architectures [94]
Machine learning models trained to emulate the
input output behavior of scientific simulations.
Usually, these models are trained as accelerated
oracles for computing how simulations will
perform at new parameters.
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A model with known, observable and/or interpretable relationships between variables.
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